Obesity Management Drugs Market, By Drug Type (Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, Liraglutide), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, E-commerce), and By Region (North America, Latin Ame

Obesity Management Drugs Market, By Drug Type (Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, Liraglutide), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, E-commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Obesity is defined as excess body fat accumulation. The major factors contributing to obesity throughout the world are diseases and adoption of unhealthy life. Increasing prevalence of obesity in developed and emerging economies of the world is projected to propel the growth of the market during the forecasted period. For instance, according to reports published by the World Federation of Obesity, roughly 27.4 million children in India will be obese by 2030. This rapid increase in childhood obesity in India is expected to increase demand for weight loss and obesity management techniques during the forecast period.
Restraints of the Global Obesity Management Drugs Market
Major factors hampering the growth of the obesity management drugs market during the forecast period constitutes of lack of proper healthcare infrastructure along with improper development and implementation of clinical practice guidelines.
Key features of the study:
This report provides in-depth analysis of the global obesity management drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global obesity management drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include F Hoffmann La Roche Ltd., GlaxoSmithKline plc., Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc., VIVUS, Inc., Novo Nordisk A/S, and Eisai Co., Ltd.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global obesity management drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Global Obesity Management Drugs Market, By Drug Type:
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
Global Obesity Management Drugs Market, By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Global Obesity Management Drugs Market, By Geography:
North America
By Drug Type
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
By Distribution Channel
Hospitals Pharmacies
Retail Pharmacies
E-commerce
By Country:
U.S.
Canada
Europe
By Drug Type
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
By Distribution Channel
Hospitals Pharmacies
Retail Pharmacies
E-commerce
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
By Distribution Channel
Hospitals Pharmacies
Retail Pharmacies
E-commerce
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Drug Type
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
By Distribution Channel
Hospitals Pharmacies
Retail Pharmacies
E-commerce
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
By Drug Type
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
By Distribution Channel
Hospitals Pharmacies
Retail Pharmacies
E-commerce
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Type
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
By Distribution Channel
Hospitals Pharmacies
Retail Pharmacies
E-commerce
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
F Hoffmann La Roche Ltd.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
GlaxoSmithKline plc.
Orexigen Therapeutics, Inc.
Arena Pharmaceuticals, Inc.
VIVUS, Inc.
Novo Nordisk A/S
Eisai Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section.